-
JNJ-10198409: PDGF Receptor Inhibitor Workflows
2026-08-24
JNJ-10198409 enables controlled interrogation of PDGF-BB receptor signaling in proliferation, angiogenesis, tumor-model, and fibrotic disorder research. Its nanomolar cellular potency and ATP-competitive mechanism support time-resolved, dose-responsive workflows rather than relying on endpoint viability alone.
-
Protein A/G Magnetic Beads for IP Workflows
2026-08-24
Protein A/G Magnetic Beads provide Fc-dependent capture of IgG antibodies for antibody purification, immunoprecipitation, co-immunoprecipitation, and Ch-IP from complex samples. They should be optimized for each antibody and matrix and should not be treated as a universal capture reagent or as a diagnostic or medical product.
-
Liproxstatin-1: Ferroptosis Inhibitor Workflows
2026-08-23
Liproxstatin-1 provides a practical way to distinguish ferroptotic lipid damage from apoptosis and nonspecific oxidative injury. This guide translates its nanomolar cell-based activity into assay workflows for GPX4-deficient systems, salivary-gland oxidative stress, and renal injury research, with troubleshooting guidance for reproducible results.
-
Wnt–EGFR Control of DNA Damage Responses
2026-08-22
Ewen-Campen and Perrimon show that canonical Wnt signaling protects cells in the Drosophila wing imaginal disc from DNA damage-induced apoptosis by activating EGFR through the ligand-processing protease Rhomboid. The study connects tissue growth and patterning signals with Chk2-, p53-, and E2F1-dependent DNA damage responses, providing a mechanistic framework for understanding context-specific damage sensitivity.
-
Lumiracoxib and the Timing of COX-2 Repair
2026-08-22
Lumiracoxib is more than a conventional anti-inflammatory compound: it is a time-resolved probe for understanding how cyclooxygenase-2 pathway modulation can produce opposing effects during ischemia and tissue repair. This thought-leadership article translates recent muscle-injury findings into practical guidance for selective COX-2 experiments, assay design, and translational interpretation.
-
EphA2 Synthetic Lethality in MYC-Driven TNBC
2026-08-21
Ye and colleagues used a chemogenetic screen of kinase inhibitors to identify EphA2 inhibition as a selective vulnerability in MYC-driven triple-negative breast cancer. The lead compound ALW-II-41-27 induced p53-independent intrinsic apoptosis and reduced growth of two TNBC xenograft models, supporting EphA2 as a candidate MYC-directed dependency while leaving important questions about pharmacological selectivity and clinical translation.
-
Cyclosporin A: A Mechanism-First Assay Guide
2026-08-20
Cyclosporin A and cyclosporine are powerful tools for dissecting cyclophilin, calcineurin-NFAT, mitochondrial, and immune biology. This mechanism-first guide shows how to design interpretable assays while avoiding confounding effects from solubility, transport, uptake, and cytotoxicity.
-
WIP1, p38 MAPK, and Pyroptosis in Septic AKI
2026-08-20
The reference study identifies WIP1/PPM1D as a suppressor of renal tubular pyroptosis in sepsis-associated acute kidney injury, acting in part by restraining p38 MAPK phosphorylation. Its combination of single-cell analysis, human acute tubular injury samples, LPS-injured mice, and HK2 cell experiments provides a mechanistic framework for interpreting WIP1 as a potential regulator of inflammatory kidney damage.
-
Elobixibat Hydrate: A Compartment-First Guide
2026-08-19
Elobixibat hydrate is an ileal bile acid transporter inhibitor whose strongest pharmacological signal may occur in the gut rather than plasma. This guide translates its bile acid, TGR5, GLP-1, and FXR-linked biology into practical assay decisions across constipation, colonoscopy preparation, and metabolic research.
-
JC-1 for Mitochondrial Membrane Potential Assays
2026-08-19
JC-1 converts mitochondrial polarization into a practical red-to-green fluorescence ratio for apoptosis detection, mitochondrial dysfunction research, and cellular bioenergetics studies. This guide connects that assay to ferroptosis-focused pulmonary fibrosis research while emphasizing controls, workflow execution, and interpretation limits.
-
N1-Methyl-Pseudouridine-5'-Triphosphate Workflow
2026-08-18
Build more stable, translation-ready RNA by integrating N1-Methyl-Pseudouridine-5'-Triphosphate into controlled in vitro transcription workflows. The same quality-by-design approach supports reporter assays, mRNA vaccine development, and emerging inhaled RNA strategies for remodeling hostile tumor microenvironments.
-
Smg5–Hnrnpl–Mag Axis in Oligodendrocyte Maturation
2026-08-18
The reference study identifies SMG5-dependent nonsense-mediated mRNA decay as an essential post-transcriptional regulator of oligodendrocyte differentiation and CNS myelination. Its findings connect clearance of aberrant Hnrnpl transcripts with HNRNPL-controlled alternative splicing of Mag and Nfasc, providing a mechanistic framework for understanding how RNA quality control influences myelin development.
-
HDAC Inhibitors Repress NUT Function in NUT Carcinoma
2026-08-17
This study developed a dCAS9-based transcriptional screen to identify compounds that suppress the oncogenic activity of BRD4-NUT in NUT carcinoma. It revealed that structurally distinct HDAC inhibitors can repress megadomain-driven transcription, induce tumor-cell differentiation, and enhance the activity of bromodomain inhibition in xenograft models.
-
A-769662 for Reliable AMPK Assays
2026-08-17
A practical, scenario-based guide to using A-769662 (SKU A3963) in cell viability, proliferation, cytotoxicity, and energy-metabolism workflows. It connects dose selection, DMSO handling, proteasome-related confounding, autophagy interpretation, and evidence-based product selection.
-
PD 173074: A Causal Assay Strategy for PAAD
2026-08-16
PD 173074 is more than a selective FGFR1 probe: it can help test whether computationally prioritized signaling dependencies in pancreatic adenocarcinoma are pharmacologically actionable. This article presents a causal assay framework that separates FGFR biology, VEGFR2 effects, and pyroptosis-related hypotheses.